Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies998
Probiomed
PROBIOMED is a Mexican biopharmaceutical company that develops and sells pharmaceutical products for human health.
Sector
Subsector
Location
Perha Pharmaceuticals
Perha Pharmaceuticals is a biotech company that focuses on researching and developing kinase inhibitors.
Sector
Subsector
Location
total rounds
total raised
G3 Pharmaceuticals
G3 Pharmaceuticals is developing novel pharmaceuticals that inhibit galectin-3 for the treatment of serious medical conditions.
Sector
Subsector
Keywords
Location
Anji Pharmaceuticals
Anji Pharma is a global pharmaceutical company focused on innovative medicines.
Sector
Subsector
Keywords
Location
total rounds
total raised
M&A Details1
Transaction name
Acquired by
Genentech
announced date
price
Financials
Funding Rounds1
Number of Funding Rounds
Money Raised
Their latest funding was raised on 16.10.2013. Their latest investor OrbiMed. Their latest round Series A
OrbiMed
OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Topspin Medical
Topspin Medical is an Israeli company that developed a miniaturized MRI technology.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
The Column Group
The Column Group is a venture capital firm focused on creating the next generation of biotechnology companies.
Sector
Subsector
Location
count Of Investments
count Of Exists
venBio Partners
venBio is a life sciences investment firm that partners with industry leaders to develop groundbreaking medicines.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Aisling Capital
Aisling Capital is a venture capital firm based in New York that focuses on investing in the pharmaceutical and biotechnology sectors.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors5
Number of lead investors
Number of investors
OrbiMed
OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Carl L. Gordon
Carl Gordon is a founding General Partner of OrbiMed and Co-Head of Private Equity. Carl Gordon is active in both private equity and small-capitalization public equity investments.He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997.He was a Fellow at The Rockefeller University from 1993 to 1995. Carl Gordon received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology. His doctoral work involved studies of protein folding and assembly. He received a Bachelors degree from Harvard College.
current job
Topspin Medical
Topspin Medical is an Israeli company that developed a miniaturized MRI technology.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
The Column Group
The Column Group is a venture capital firm focused on creating the next generation of biotechnology companies.
Sector
Subsector
Location
count Of Investments
count Of Exists
People
Founders1
Richard Heyman
Richard A. Heyman, PhD, has 20 years of drug discovery experience in the biotech sector and, most recently, cofounded Aragon Pharmaceuticals in 2009. Previously, he was Chief Scientific Officer at Kalypsys, Inc., where he conducted drug discovery in therapeutic areas such as metabolic diseases, pain, and inflammation. In 1999, he cofounded and served as Chief Scientific Officer of X-Ceptor Therapeutics, a company that developed compounds targeting nuclear receptors for the treatment of metabolic diseases. X-Ceptor was acquired by Exelixis in 2004. Before X-Ceptor, he was Vice President of Research at Ligand Pharmaceuticals and was project leader for multiple discovery programs, including the successful identification and development of Panretin® and Targretin®, retinoids approved by the FDA for the treatment of cancer. He was an NIH postdoctoral fellow and staff scientist at the Salk Institute for Biological Studies. He received a PhD in pharmacology from the University of Minnesota and a BS in chemistry from the University of Connecticut.
current job
organization founded
Richard Heyman